id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-271814-a2vlkwce	Brough, Helen A.	Managing childhood allergies and immunodeficiencies during respiratory virus epidemics – The 2020 COVID‐19 pandemic: A statement from the EAACI‐section on pediatrics	2020-05-31		.txt	text/plain	2929	172	46	In addition, there is no evidence that currently available asthma and allergy treatments, including antihistamines, corticosteroids, and bronchodilators, increase the risk of severe disease from COVID‐19. allergy, asthma, biologics, children, coronavirus, corticosteroids, COVID-19, immunodeficiency, SARS-CoV-2, treatment clinically diagnosed, but not virologically confirmed. The care of children with allergies or immune conditions is being adapted to the current situation, with more remote working and providing guidance to children to reduce likelihood of infection in children who would be deemed at higher risk of severe COVID-19 disease. Evaluating asthma and allergy more specifically as potential risk factors, a retrospective study based on electronic medical records from 140 hospitalized COVID-19 adult patients investigated pre-existing asthma or allergic diseases. As a joint project, questionThe current COVID-19 pandemic might also pose a risk to pediatric patients with secondary immunodeficiencies, such as patients on immunosuppressive therapy for autoimmune or severe allergic diseases.	./cache/cord-271814-a2vlkwce.txt	./txt/cord-271814-a2vlkwce.txt